HIMS is still up for the month of June, but the stock is reeling do to legal efforts from Eli Lilly ( NYSE:LLY ) against Hims & Hers Health compounded version of GLP-1 weight loss therapy, tirzepatide which was recently announced and slated for sale in the coming months. With more vigorous legal action taking place on Thursday.